{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T05:31:03Z","timestamp":1784352663803,"version":"3.55.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s11864-022-01016-5","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T05:02:30Z","timestamp":1665118950000},"page":"1548-1565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Treatment Options for Recurrent Primary CNS Lymphoma"],"prefix":"10.1007","volume":"23","author":[{"given":"Leon D.","family":"Kaulen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim M.","family":"Baehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"1016_CR1","doi-asserted-by":"crossref","unstructured":"Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 2021;23(12 Suppl 2):iii1-iii105.","DOI":"10.1093\/neuonc\/noab200"},{"issue":"3","key":"1016_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/neuonc\/noy192","volume":"21","author":"C Grommes","year":"2019","unstructured":"Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol. 2019;21(3):296\u2013305.","journal-title":"Neuro Oncol."},{"issue":"14","key":"1016_CR3","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1182\/blood-2013-06-453084","volume":"122","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P. How I treat CNS lymphomas. Blood. 2013;122(14):2318\u201330.","journal-title":"Blood."},{"issue":"8","key":"1016_CR4","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1016\/S2352-3026(16)30050-3","volume":"3","author":"G Illerhaus","year":"2016","unstructured":"Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, Wolf HH, Hirt C, Stilgenbauer S, Binder M, Hau P, Edinger M, Frickhofen N, Bentz M, M\u00f6hle R, R\u00f6th A, Pfreundschuh M, von Baumgarten L, Deckert M, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol. 2016;3(8):e388\u201397.","journal-title":"Lancet Haematol."},{"key":"1016_CR5","doi-asserted-by":"crossref","unstructured":"\u2022 DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10(4):635-43. Note: This reference is of outstanding importance as this paradigm shifting trial demonstrated the significant survival benefit resulting from the addition of HD-MTX to conventional WBRT in PCNSL patients.","DOI":"10.1200\/JCO.1992.10.4.635"},{"key":"1016_CR6","doi-asserted-by":"crossref","unstructured":"\u2022 Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21(6):1044-9. Note: This reference is of outstanding importance as this trial suggested that HD-MTX without additional WBRT results in similar outcome and lower toxicity rates.","DOI":"10.1200\/JCO.2003.03.036"},{"issue":"11","key":"1016_CR7","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Ros\u00e9e P, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510\u2013e23.","journal-title":"Lancet Haematol."},{"issue":"10","key":"1016_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Molu\u00e7on-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol. 2019;37(10):823\u201333.","journal-title":"J Clin Oncol."},{"issue":"2","key":"1016_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11060-006-9165-6","volume":"80","author":"K Jahnke","year":"2006","unstructured":"Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, Korfel A, on behalf of the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG). Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006;80(2):159\u201365.","journal-title":"J Neurooncol."},{"issue":"5","key":"1016_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/neuonc\/nor014","volume":"13","author":"L Nayak","year":"2011","unstructured":"Nayak L, Hedvat C, Rosenblum MK, Abrey LE, DeAngelis LM. Late relapse in primary central nervous system lymphoma: clonal persistence. Neuro Oncol. 2011;13(5):525\u20139.","journal-title":"Neuro Oncol."},{"issue":"9","key":"1016_CR11","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/neuonc\/now033","volume":"18","author":"S Langner-Lemercier","year":"2016","unstructured":"Langner-Lemercier S, Houillier C, Soussain C, Ghesqui\u00e8res H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau MP, Molu\u00e7on-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, et al. Primary CNS lymphoma at first relapse\/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 2016;18(9):1297\u2013303.","journal-title":"Neuro Oncol."},{"key":"1016_CR12","doi-asserted-by":"crossref","unstructured":"\u2022 Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004;10(17):5643-6. Note: This reference is of importance as this retrospective clinical study revealed HD-MTX remains an effective treatment in recurrent primary CNS lymphoma cases with initial response to HD-MTX-based first-line therapy.","DOI":"10.1158\/1078-0432.CCR-04-0159"},{"issue":"1","key":"1016_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11060-014-1370-0","volume":"117","author":"E Pentsova","year":"2014","unstructured":"Pentsova E, Deangelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neurooncol. 2014;117(1):161\u20135.","journal-title":"J Neurooncol."},{"key":"1016_CR14","doi-asserted-by":"crossref","unstructured":"\u2022 Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, et al. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia. 2017;31(12):2623-9. Note: This study is of importance as it showed that high-dose chemotherapy followed by autologous stem cell transplantation appears to be an effective treatment for selected patients with recurrent primary CNS lymphoma resulting in promising outcome and moderate toxicities.","DOI":"10.1038\/leu.2017.170"},{"issue":"11","key":"1016_CR15","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1212\/01.wnl.0000276986.19602.c1","volume":"69","author":"AF Hottinger","year":"2007","unstructured":"Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology. 2007;69(11):1178\u201382.","journal-title":"Neurology."},{"issue":"7","key":"1016_CR16","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1200\/JCO.2005.01.161","volume":"23","author":"PL Nguyen","year":"2005","unstructured":"Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005;23(7):1507\u201313.","journal-title":"J Clin Oncol."},{"issue":"3","key":"1016_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/neuonc\/noy193","volume":"21","author":"C Grommes","year":"2019","unstructured":"Grommes C, Nayak L, Tun HW, Batchelor TT. Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol. 2019;21(3):306\u201313.","journal-title":"Neuro Oncol."},{"issue":"9","key":"1016_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11864-020-00758-4","volume":"21","author":"P Kim","year":"2020","unstructured":"Kim P, Omuro A. Consolidation therapy in primary central nervous system lymphoma. Curr Treat Options Oncol. 2020;21(9):74.","journal-title":"Curr Treat Options Oncol."},{"issue":"7","key":"1016_CR19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","volume":"127","author":"B Chapuy","year":"2016","unstructured":"Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869\u201381.","journal-title":"Blood."},{"issue":"2","key":"1016_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/bjh.17319","volume":"193","author":"LD Kaulen","year":"2021","unstructured":"Kaulen LD, Erson-Omay EZ, Henegariu O, Karschnia P, Huttner A, G\u00fcnel M, Baehring JM. Exome sequencing identifies SLIT2 variants in primary CNS lymphoma. Br J Haematol. 2021;193(2):375\u20139.","journal-title":"Br J Haematol."},{"issue":"6","key":"1016_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00401-016-1536-2","volume":"131","author":"K Fukumura","year":"2016","unstructured":"Fukumura K, Kawazu M, Kojima S, Ueno T, Sai E, Soda M, Ueda H, Yasuda T, Yamaguchi H, Lee J, Shishido-Hara Y, Sasaki A, Shirahata M, Mishima K, Ichimura K, Mukasa A, Narita Y, Saito N, Aburatani H, et al. Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol. 2016;131(6):865\u201375.","journal-title":"Acta Neuropathol."},{"issue":"17","key":"1016_CR22","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","volume":"21","author":"E Braggio","year":"2015","unstructured":"Braggio E, Van Wier S, Ojha J, McPhail E, Asmann YW, Egan J, et al. Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res. 2015;21(17):3986\u201394.","journal-title":"Clin Cancer Res."},{"key":"1016_CR23","doi-asserted-by":"crossref","unstructured":"\u2022 Vater I, Montesinos-Rongen M, Schlesner M, Haake A, Purschke F, Sprute R, et al. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia. 2015;29(3):677-85. Note: This reference is of importance as it represents a high quality exome sequencing study of this rare entity, which provided insights into the genetic landscape of primary CNS lymphomas thereby paving the way for novel targeted therapies.","DOI":"10.1038\/leu.2014.264"},{"key":"1016_CR24","doi-asserted-by":"crossref","unstructured":"\u2022 Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial. Blood. 2022;139(15):2306-15. Note: This reference is of importance as it demonstrated the safety and efficacy of CAR-T cell therapy for primary CNS lymphomas, which were excluded from most early clinical trials due to the concern for immune effector cell-associated neurotoxicity syndrome.","DOI":"10.1182\/blood.2021014738"},{"issue":"21","key":"1016_CR25","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1212\/WNL.0000000000200608","volume":"98","author":"P Karschnia","year":"2022","unstructured":"Karschnia P, Rejeski K, Winkelmann M, Sch\u00f6berl F, B\u00fccklein VL, Blumenberg V, Schmidt C, Blobner J, von Bergwelt-Baildon M, Tonn JC, Kunz WG, Subklewe M, von Baumgarten L. Toxicities and response rates of secondary CNS lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T cells. Neurology. 2022;98(21):884\u20139.","journal-title":"Neurology."},{"issue":"23","key":"1016_CR26","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","volume":"129","author":"L Nayak","year":"2017","unstructured":"Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, Armand P, Rodig SJ, Shipp MA. PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071\u20133.","journal-title":"Blood."},{"key":"1016_CR27","doi-asserted-by":"crossref","unstructured":"Kaulen LD, Gumbinger C, Hinz F, Kessler T, Winkler F, Bendszus M, et al. Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma. Neurooncol Adv. 2022;4(1):vdac051.","DOI":"10.1093\/noajnl\/vdac051"},{"key":"1016_CR28","doi-asserted-by":"crossref","unstructured":"\u2022 Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma. Blood. 2019;133(5):436-45. Note: This reference is of importance as this clinical trial revealed that targeted treatment approaches with bruton tyrosine kinase inhibitor, ibrutinib, may be combined with HD-MTX and rituximab therapy, which resulted in acceptable toxicity profiles and promising overall response rates in recurrent primary CNS lymphoma.","DOI":"10.1182\/blood-2018-09-875732"},{"issue":"13","key":"1016_CR29","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1212\/WNL.0000000000012515","volume":"97","author":"C Houillier","year":"2021","unstructured":"Houillier C, Chabrot CM, Moles-Moreau MP, Willems L, Ahle G, Waultier-Rascalou A, Fornecker LM, Hoang-Xuan K, Soussain C. Rituximab-lenalidomide-ibrutinib combination for relapsed\/refractory primary CNS lymphoma: a case series of the LOC network. Neurology. 2021;97(13):628\u201331.","journal-title":"Neurology."},{"issue":"4","key":"1016_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"H Ghesquieres","year":"2019","unstructured":"Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Molu\u00e7on-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u2018proof of concept\u2019 phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)\u2020. Ann Oncol. 2019;30(4):621\u20138.","journal-title":"Ann Oncol."},{"issue":"13","key":"1016_CR31","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","volume":"2","author":"JL Rubenstein","year":"2018","unstructured":"Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, Wang X, Chen N, Gangoiti J, Munster PN, Damato B. Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018;2(13):1595\u2013607.","journal-title":"Blood Adv."},{"key":"1016_CR32","doi-asserted-by":"crossref","unstructured":"Schaff LR, Grommes C. Update on novel therapeutics for primary CNS lymphoma. Cancers (Basel). 2021;13(21).","DOI":"10.3390\/cancers13215372"},{"issue":"5","key":"1016_CR33","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Ros\u00e9e PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rud\u00e0 R, Binder M, Pukrop T, Balzarotti M, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217\u201327.","journal-title":"Lancet Haematol."},{"issue":"25","key":"1016_CR34","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","volume":"31","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061\u20138.","journal-title":"J Clin Oncol."},{"issue":"6","key":"1016_CR35","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","volume":"2","author":"A Omuro","year":"2015","unstructured":"Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barri\u00e9 M, del Rio MS, Gonzalez-Aguilar A, Houillier C, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015;2(6):e251\u20139.","journal-title":"Lancet Haematol."},{"issue":"9","key":"1016_CR36","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403\u201310.","journal-title":"Blood."},{"key":"1016_CR37","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","volume":"36","author":"AJM Ferreri","year":"2022","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, la Ros\u00e9e P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, G\u00f8rl\u00f8v JS, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022;36:1870\u20138.","journal-title":"Leukemia."},{"issue":"31","key":"1016_CR38","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","volume":"31","author":"PG Morris","year":"2013","unstructured":"Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971\u20139.","journal-title":"J Clin Oncol."},{"issue":"14","key":"1016_CR39","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1200\/JCO.2015.64.8634","volume":"34","author":"J Glass","year":"2016","unstructured":"Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, Bokstein F, Bovi JA, Solhjem MC, Mehta MP. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227. J Clin Oncol. 2016;34(14):1620\u20135.","journal-title":"J Clin Oncol."},{"issue":"4","key":"1016_CR40","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/leu.2016.334","volume":"31","author":"K Fritsch","year":"2017","unstructured":"Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, M\u00f6hle R, L\u00f6w S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, He\u00df G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017;31(4):846\u201352.","journal-title":"Leukemia."},{"key":"1016_CR41","doi-asserted-by":"crossref","unstructured":"\u2022 Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle Osseuse-Th\u00e9rapie Cellulaire. J Clin Oncol. 2008;26(15):2512-8. Note: This reference is of oustanding importance as this prospective trial revealed that intensive polychemotherapy followed by autologous stem cell transplantation is an effective and safe treatment option for selected patients with recurrent primary CNS lymphoma.","DOI":"10.1200\/JCO.2007.13.5533"},{"issue":"3","key":"1016_CR42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/hon.2037","volume":"31","author":"S Mappa","year":"2013","unstructured":"Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Sorar\u00f9 M, Vianello F, Baldini L, Proserpio I, Foppoli M, Assanelli A, Reni M, Caligaris-Cappio F, Ferreri AJM. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Hematol Oncol. 2013;31(3):143\u201350.","journal-title":"Hematol Oncol."},{"issue":"20","key":"1016_CR43","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1182\/bloodadvances.2021004779","volume":"5","author":"CP Fox","year":"2021","unstructured":"Fox CP, Ali AS, McIlroy G, Thust S, Martinez-Calle N, Jackson AE, Hopkins LM, Thomas CM, Kassam S, Wright J, Chaganti S, Smith J, Chau I, Culligan D, Linton KM, Collins GP, Ferreri AJM, Lewis D, Davies AJ, et al. A phase 1\/2 study of thiotepa-based immunochemotherapy in relapsed\/refractory primary CNS lymphoma: the TIER trial. Blood Adv. 2021;5(20):4073\u201382.","journal-title":"Blood Adv."},{"issue":"10","key":"1016_CR44","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1212\/WNL.0b013e31820f2d94","volume":"76","author":"TT Batchelor","year":"2011","unstructured":"Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011;76(10):929\u201330.","journal-title":"Neurology."},{"issue":"15","key":"1016_CR45","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1200\/JCO.2015.64.9897","volume":"34","author":"A Korfel","year":"2016","unstructured":"Korfel A, Schlegel U, Herrlinger U, Dreyling M, Schmidt C, von Baumgarten L, Pezzutto A, Grobosch T, Kebir S, Thiel E, Martus P, Kiewe P. Phase II trial of temsirolimus for relapsed\/refractory primary CNS lymphoma. J Clin Oncol. 2016;34(15):1757\u201363.","journal-title":"J Clin Oncol."},{"issue":"2","key":"1016_CR46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11060-007-9464-6","volume":"86","author":"AD Voloschin","year":"2008","unstructured":"Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol. 2008;86(2):211\u20135.","journal-title":"J Neurooncol."},{"issue":"7","key":"1016_CR47","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/annonc\/mdl070","volume":"17","author":"L Fischer","year":"2006","unstructured":"Fischer L, Thiel E, Klasen HA, Birkmann J, Jahnke K, Martus P, Korfel A. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006;17(7):1141\u20135.","journal-title":"Ann Oncol."},{"issue":"11","key":"1016_CR48","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.ejca.2004.03.008","volume":"40","author":"M Reni","year":"2004","unstructured":"Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, Dell'Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJM. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer. 2004;40(11):1682\u20138.","journal-title":"Eur J Cancer."},{"issue":"15","key":"1016_CR49","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1002\/cncr.26709","volume":"118","author":"JJ Raizer","year":"2012","unstructured":"Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, Getch CC, Tellez C, Grimm SA. Pemetrexed in the treatment of relapsed\/refractory primary central nervous system lymphoma. Cancer. 2012;118(15):3743\u20138.","journal-title":"Cancer."},{"issue":"1","key":"1016_CR50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/10428194.2012.698736","volume":"54","author":"L Nayak","year":"2013","unstructured":"Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM, Omuro A, for the North American Brain Tumor Consortium. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2013;54(1):58\u201361.","journal-title":"Leuk Lymphoma."},{"issue":"5","key":"1016_CR51","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1212\/01.WNL.0000137050.43114.42","volume":"63","author":"RH Enting","year":"2004","unstructured":"Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology. 2004;63(5):901\u20133.","journal-title":"Neurology."},{"issue":"5","key":"1016_CR52","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1182\/blood-2012-07-440974","volume":"121","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013;121(5):745\u201351.","journal-title":"Blood."},{"issue":"11","key":"1016_CR53","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","volume":"25","author":"JL Rubenstein","year":"2007","unstructured":"Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25(11):1350\u20136.","journal-title":"J Clin Oncol."},{"issue":"1","key":"1016_CR54","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/jnnp.71.1.118","volume":"71","author":"U Schlegel","year":"2001","unstructured":"Schlegel U, Pels H, Glasmacher A, Kleinschmidt R, Schmidt-Wolf I, Helmstaedter C, Fliessbach K, Deckert M, van Roost D, Fimmers R, Bode U, Klockgether T. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry. 2001;71(1):118\u201322.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"1","key":"1016_CR55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-S","volume":"23","author":"DF Nelson","year":"1992","unstructured":"Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, Thomson JW, Murray KJ. Non-Hodgkin\u2019s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9\u201317.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"1016_CR56","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/neuonc\/nor186","volume":"14","author":"DD Correa","year":"2012","unstructured":"Correa DD, Shi W, Abrey LE, Deangelis LM, Omuro AM, Deutsch MB, et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol. 2012;14(1):101\u20138.","journal-title":"Neuro Oncol."},{"key":"1016_CR57","doi-asserted-by":"crossref","unstructured":"Batchelor T, Giri S, Ruppert AS, Bartlett NL, Hsi ED, Cheson BD, et al. Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: results of CALGB 51101 (Alliance). J Clin Oncol. 2021;39(15_suppl):7506-.","DOI":"10.1200\/JCO.2021.39.15_suppl.7506"},{"issue":"10","key":"1016_CR58","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1001\/archneur.62.10.1595","volume":"62","author":"AM Omuro","year":"2005","unstructured":"Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, Deangelis LM, Abrey LE. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005;62(10):1595\u2013600.","journal-title":"Arch Neurol."},{"issue":"28","key":"1016_CR59","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","volume":"24","author":"IT Gavrilovic","year":"2006","unstructured":"Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24(28):4570\u20134.","journal-title":"J Clin Oncol."},{"issue":"11","key":"1016_CR60","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","volume":"11","author":"E Thiel","year":"2010","unstructured":"Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, R\u00f6th A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leith\u00e4user M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, N\u00e4gele T, Pietsch T, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036\u201347.","journal-title":"Lancet Oncol."},{"issue":"30","key":"1016_CR61","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","volume":"25","author":"GD Shah","year":"2007","unstructured":"Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25(30):4730\u20135.","journal-title":"J Clin Oncol."},{"issue":"3","key":"1016_CR62","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11060-019-03257-1","volume":"144","author":"DD Correa","year":"2019","unstructured":"Correa DD, Braun E, Kryza-Lacombe M, Ho KW, Reiner AS, Panageas KS, Yahalom J, Sauter CS, Abrey LE, DeAngelis LM, Omuro A. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. J Neurooncol. 2019;144(3):553\u201362.","journal-title":"J Neurooncol."},{"issue":"4","key":"1016_CR63","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1158\/1078-0432.CCR-11-0625","volume":"18","author":"MJ Wieduwilt","year":"2012","unstructured":"Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O'Brien J, Shuman MA, Cha S, Damon LE, Rubenstein JL. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012;18(4):1146\u201355.","journal-title":"Clin Cancer Res."},{"key":"1016_CR64","doi-asserted-by":"crossref","unstructured":"Mutter JA, Alig S, Lauer EM, Esfahani MS, Mitschke J, Kurtz DM, et al. Profiling of circulating tumor DNA for noninvasive disease detection, risk stratification, and MRD monitoring in patients with CNS lymphoma. Blood. 2021;138(Supplement 1):6-.","DOI":"10.1182\/blood-2021-149644"},{"issue":"5","key":"1016_CR65","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1182\/blood.2020010137","volume":"138","author":"M Gupta","year":"2021","unstructured":"Gupta M, Burns EJ, Georgantas NZ, Thierauf J, Nayyar N, Gordon A, Jones SAS, Pisapia M, Sun Y, Burns RP, Velarde J, Jordan JT, Frigault MJ, Nahed BV, Jones PS, Barker FG, Curry WT, Gupta R, Batchelor TT, et al. A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood. 2021;138(5):382\u20136.","journal-title":"Blood."},{"key":"1016_CR66","doi-asserted-by":"crossref","unstructured":"Grommes C, Pentsova E, Nolan C, Wolfe J, Mellinghoff IK, Deangelis L. Phase II study of single agent buparlisib in recurrent\/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Ann Oncol. 2016;27:vi106.","DOI":"10.1093\/annonc\/mdw367.13"},{"key":"1016_CR67","doi-asserted-by":"crossref","unstructured":"Grommes C, Gavrilovic I, Miller AM, Stone JB, Kaley T, Madzsar JT, et al. Phase Ib of copanlisib in combination with ibrutinib in recurrent\/refractory primary CNS lymphoma (PCNSL). Blood. 2019;134(Supplement_1):1598-.","DOI":"10.1182\/blood-2019-126214"},{"issue":"1","key":"1016_CR68","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1212\/WNL.0000000000003420","volume":"88","author":"K Chamoun","year":"2017","unstructured":"Chamoun K, Choquet S, Boyle E, Houillier C, Larrieu-Ciron D, Al Jijakli A, et al. Ibrutinib monotherapy in relapsed\/refractory CNS lymphoma: a retrospective case series. Neurology. 2017;88(1):101\u20132.","journal-title":"Neurology."},{"key":"1016_CR69","doi-asserted-by":"crossref","unstructured":"Choquet S, Houillier C, Bijou F, Houot R, Boyle E, Gressin R, et al. Ibrutinib monotherapy in relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreo-retinal lymphoma (PVRL). Result of the interim analysis of the iLOC phase II study from the Lysa and the French LOC Network. Blood. 2016;128(22):784-.","DOI":"10.1182\/blood.V128.22.784.784"},{"issue":"9","key":"1016_CR70","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, et al. Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018\u201329.","journal-title":"Cancer Discov."},{"issue":"8","key":"1016_CR71","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922\u20136.","journal-title":"Nat Med."},{"issue":"15","key":"1016_CR72","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, et al. Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2015;372(15):1430\u201340.","journal-title":"N Engl J Med."},{"key":"1016_CR73","doi-asserted-by":"crossref","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833-43.e5.","DOI":"10.1016\/j.ccell.2017.04.012"},{"issue":"1","key":"1016_CR74","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00277-012-1569-0","volume":"92","author":"EN Oliva","year":"2013","unstructured":"Oliva EN, Cuzzola M, Aloe Spiriti MA, Poloni A, Lagan\u00e0 C, Rigolino C, Morabito F, Galimberti S, Ghio R, Cortelezzi A, Palumbo GA, Sanpaolo G, Finelli C, Ricco A, Volpe A, Rod\u00e0 F, Breccia M, Alimena G, Nobile F, Latagliata R. Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. Ann Hematol. 2013;92(1):25\u201332.","journal-title":"Ann Hematol."},{"issue":"1-2","key":"1016_CR75","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","volume":"69","author":"K Dredge","year":"2005","unstructured":"Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005;69(1-2):56\u201363.","journal-title":"Microvasc Res."},{"issue":"21","key":"1016_CR76","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1182\/blood-2018-02-835496","volume":"132","author":"HW Tun","year":"2018","unstructured":"Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018;132(21):2240\u20138.","journal-title":"Blood."},{"issue":"48","key":"1016_CR77","doi-asserted-by":"publisher","first-page":"24275","DOI":"10.1073\/pnas.1903854116","volume":"116","author":"M Mulazzani","year":"2019","unstructured":"Mulazzani M, Fr\u00e4\u00dfle SP, von M\u00fccke-Heim I, Langer S, Zhou X, Ishikawa-Ankerhold H, Leube J, Zhang W, D\u00f6tsch S, Svec M, Rudelius M, Dreyling M, von Bergwelt-Baildon M, Straube A, Buchholz VR, Busch DH, von Baumgarten L. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice. Proc Natl Acad Sci U S A. 2019;116(48):24275\u201384.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1016_CR78","doi-asserted-by":"crossref","unstructured":"Karschnia P, Blobner J, Teske N, Sch\u00f6berl F, Fitzinger E, Dreyling M, et al. CAR T-cells for CNS lymphoma: driving into new terrain? Cancers (Basel). 2021;13(10).","DOI":"10.3390\/cancers13102503"},{"issue":"1","key":"1016_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med."},{"issue":"5","key":"1016_CR80","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, de Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med."},{"issue":"8","key":"1016_CR81","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMc1704610","volume":"377","author":"JS Abramson","year":"2017","unstructured":"Abramson JS, McGree B, Noyes S, Plummer S, Wong C, Chen YB, Palmer E, Albertson T, Ferry JA, Arrillaga-Romany IC. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med. 2017;377(8):783\u20134.","journal-title":"N Engl J Med."},{"issue":"11","key":"1016_CR82","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1182\/blood.2019001694","volume":"134","author":"MJ Frigault","year":"2019","unstructured":"Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, Chen YB, Abramson J, Crombie J, Armand P, Nayak L, Panzini C, Riley LS, Gallagher K, Maus MV. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860\u20136.","journal-title":"Blood."},{"issue":"5","key":"1016_CR83","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/nox187","volume":"20","author":"JS Mendez","year":"2018","unstructured":"Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;20(5):687\u201394.","journal-title":"Neuro Oncol."},{"issue":"2","key":"1016_CR84","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/annonc\/mdn628","volume":"20","author":"G Illerhaus","year":"2009","unstructured":"Illerhaus G, Marks R, M\u00fcller F, Ihorst G, Feuerhake F, Deckert M, Ostertag C, Finke J. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol. 2009;20(2):319\u201325.","journal-title":"Ann Oncol."},{"issue":"7","key":"1016_CR85","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","volume":"26","author":"B Kasenda","year":"2015","unstructured":"Kasenda B, Ferreri AJ, Marturano E, Forst D, Bromberg J, Ghesquieres H, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol. 2015;26(7):1305\u201313.","journal-title":"Ann Oncol."},{"issue":"14","key":"1016_CR86","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/bloodadvances.2020002064","volume":"4","author":"E Schorb","year":"2020","unstructured":"Schorb E, Kasenda B, Ihorst G, Scherer F, Wendler J, Isbell L, Fricker H, Finke J, Illerhaus G. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. Blood Adv. 2020;4(14):3378\u201381.","journal-title":"Blood Adv."},{"issue":"1","key":"1016_CR87","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11060-019-03208-w","volume":"144","author":"LD Kaulen","year":"2019","unstructured":"Kaulen LD, Galluzzo D, Hui P, Barbiero F, Karschnia P, Huttner A, Fulbright R, Baehring JM. Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma. J Neurooncol. 2019;144(1):107\u201315.","journal-title":"J Neurooncol."},{"issue":"1","key":"1016_CR88","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11060-020-03583-9","volume":"149","author":"LD Kaulen","year":"2020","unstructured":"Kaulen LD, Karschnia P, Dietrich J, Baehring JM. Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis. J Neurooncol. 2020;149(1):153\u20139.","journal-title":"J Neurooncol."},{"issue":"12","key":"1016_CR89","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1136\/jnnp-2020-325759","volume":"92","author":"S Doubrovinskaia","year":"2021","unstructured":"Doubrovinskaia S, Sahm F, Thier MC, Bendszus M, Wick W, Seliger C, Kaulen LD. Primary CNS lymphoma after CLIPPERS: a case series. J Neurol Neurosurg Psychiatry. 2021;92(12):1348\u20139.","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"11","key":"1016_CR90","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1182\/blood.2020008520","volume":"137","author":"MK Gandhi","year":"2021","unstructured":"Gandhi MK, Hoang T, Law SC, Brosda S, O\u2019Rourke K, Tobin JWD, Vari F, Murigneux V, Fink L, Gunawardana J, Gould C, Oey H, Bednarska K, Delecluse S, Trappe RU, Merida de Long L, Sabdia MB, Bhagat G, Hapgood G, et al. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood. 2021;137(11):1468\u201377.","journal-title":"Blood."},{"key":"1016_CR91","doi-asserted-by":"crossref","unstructured":"Pei Y, Wong JHY, Robertson ES. Targeted therapies for Epstein-Barr virus-associated lymphomas. Cancers (Basel). 2020;12(9).","DOI":"10.3390\/cancers12092565"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-022-01016-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-022-01016-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-022-01016-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:13:01Z","timestamp":1666743181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-022-01016-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":91,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1016"],"URL":"https:\/\/doi.org\/10.1007\/s11864-022-01016-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"assertion":[{"value":"23 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}